#1 Clinical Trials Search in Europe

Pegfilgrastim

Pegfilgrastim is a long-acting form of filgrastim, a medication used to stimulate the production of white blood cells in patients undergoing chemotherapy. This article explores the use of pegfilgrastim in clinical trials, focusing on its effectiveness and safety in managing chemotherapy-induced neutropenia, a condition characterized by low levels of neutrophils (a type of white blood cell) that can increase the risk of infections in cancer patients.

Table of Contents

What is Pegfilgrastim?

Pegfilgrastim, also known by the brand name Neulasta®, is a long-acting form of a medication called granulocyte colony-stimulating factor (G-CSF)[1]. It’s a specially designed protein that helps stimulate the growth of neutrophils, which are a type of white blood cell crucial for fighting infections[2].

Pegfilgrastim is created by attaching a substance called polyethylene glycol (PEG) to the G-CSF molecule. This process, known as pegylation, allows the medication to stay in your body longer, requiring less frequent dosing[3].

How Does Pegfilgrastim Work?

Pegfilgrastim works by stimulating the bone marrow to produce more neutrophils. Neutrophils are a critical part of your immune system and help your body fight off bacterial infections. When you have a low neutrophil count, a condition called neutropenia, you’re at a higher risk of developing serious infections[1].

By increasing the production of neutrophils, pegfilgrastim helps to reduce the risk of infections in patients undergoing certain types of cancer treatments that can lower neutrophil counts[2].

Conditions Treated with Pegfilgrastim

Pegfilgrastim is primarily used to prevent a condition called chemotherapy-induced neutropenia. This is a common side effect of cancer treatments where the number of neutrophils in the blood becomes dangerously low. Specifically, pegfilgrastim is used in patients with:

  • Breast cancer: Particularly in patients receiving chemotherapy regimens that can cause severe neutropenia[1]
  • Non-small cell lung cancer (NSCLC): After failure of platinum-based chemotherapy[4]
  • Prostate cancer: In cases of hormone-refractory (androgen-independent) metastatic prostate cancer[4]
  • Non-Hodgkin lymphomas: Particularly in elderly patients at high risk of neutropenia from chemotherapy[5]

How is Pegfilgrastim Administered?

Pegfilgrastim is typically given as a single subcutaneous (under the skin) injection once per chemotherapy cycle. The standard dose is usually 6 mg, administered approximately 24 hours after the completion of chemotherapy[3]. In some studies, different dosages have been explored, such as 2 mg for certain conditions[6].

One of the advantages of pegfilgrastim over non-pegylated filgrastim is that it only needs to be administered once per chemotherapy cycle, rather than daily injections[1].

Effectiveness of Pegfilgrastim

Clinical trials have shown that pegfilgrastim is effective in reducing the duration of severe neutropenia in cancer patients undergoing chemotherapy. This is typically measured by the Duration of Severe Neutropenia (DSN), which is the number of consecutive days when a patient’s neutrophil count is dangerously low[1][2].

Pegfilgrastim has also been shown to reduce the incidence of febrile neutropenia, a serious condition where a patient with neutropenia develops a fever, indicating a possible infection[5].

Side Effects and Safety

While pegfilgrastim is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Bone pain
  • Injection site reactions (redness, swelling, or itching at the injection site)
  • Headache
  • Muscle aches

More serious, but less common side effects can include allergic reactions, spleen enlargement, and rarely, a serious lung problem called Acute Respiratory Distress Syndrome (ARDS)[6].

Ongoing Research and Comparisons

Researchers continue to study pegfilgrastim to optimize its use and compare it with other similar medications. Some areas of ongoing research include:

  • Biosimilars: Studies are comparing pegfilgrastim with biosimilar versions (medications that are highly similar to the original drug) to ensure they are equally safe and effective[3].
  • Comparison with other G-CSFs: Studies are comparing pegfilgrastim with other forms of G-CSF, such as lipegfilgrastim, to determine if one might be more effective or have fewer side effects[5].
  • Combination therapies: Research is exploring the use of pegfilgrastim in combination with other medications, such as plinabulin, to potentially enhance its effectiveness in preventing neutropenia[7].
  • Use in pediatric patients: Studies are investigating the use of pegfilgrastim in children with certain types of cancers[8].

These ongoing studies aim to further improve the use of pegfilgrastim and provide better outcomes for patients undergoing cancer treatments.

Aspect Details
Primary Use Management of chemotherapy-induced neutropenia in cancer patients
Administration Single subcutaneous injection, typically 24-48 hours after chemotherapy
Key Outcomes Reduction in duration of severe neutropenia, decreased incidence of febrile neutropenia
Dosage Commonly 6 mg fixed dose or weight-based dosing (e.g., 100 μg/kg)
Safety Profile Generally well-tolerated; common side effects include bone pain and injection site reactions
Ongoing Research Biosimilars, new formulations (e.g., lipegfilgrastim), optimal timing of administration
Patient Populations Studied in various cancer types, including breast cancer, lymphoma, and multiple myeloma
Pharmacokinetics Long-acting formulation allows for single dose per chemotherapy cycle

FAQ

  • What is pegfilgrastim and how does it work? Pegfilgrastim is a long-acting form of a medication that stimulates the production of white blood cells, particularly neutrophils. It works by mimicking a natural protein in your body called granulocyte colony-stimulating factor (G-CSF), which helps your bone marrow produce more neutrophils to fight off infections.
  • When is pegfilgrastim typically administered during chemotherapy? Pegfilgrastim is usually administered as a single injection about 24 hours after each chemotherapy cycle. However, some studies are exploring the possibility of administering it on the same day as chemotherapy to simplify treatment schedules.
  • What are the main benefits of using pegfilgrastim in cancer patients? The main benefits of pegfilgrastim include reducing the duration of severe neutropenia (low neutrophil count), decreasing the risk of febrile neutropenia (fever associated with low neutrophil count), and potentially allowing patients to maintain their chemotherapy schedule without delays or dose reductions.
  • Are there different forms of pegfilgrastim being studied? Yes, clinical trials are studying various forms of pegfilgrastim, including biosimilars (drugs that are highly similar to the original brand-name drug) and new formulations like lipegfilgrastim. These studies aim to provide more options for patients and potentially reduce treatment costs.
  • What are some common side effects of pegfilgrastim? Common side effects of pegfilgrastim may include bone pain, muscle aches, and injection site reactions. In clinical trials, researchers closely monitor patients for these and other potential adverse effects to ensure the drug's safety profile.

Ongoing Clinical Trials on Pegfilgrastim

  • A study comparing AZD0486 after reduced chemotherapy versus standard chemotherapy in older or unfit patients with newly diagnosed large B-cell lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Poland

  • Study of Izalontamab Brengitecan Compared to Platinum-Based Chemotherapy for Patients with Metastatic Urothelial Cancer After Immunotherapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Belgium Czechia France Germany Ireland +5

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria France Germany Greece Italy Poland +4

  • Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Finland France Germany Greece Italy The Netherlands +2

  • Study on Preventing Heart Problems in Patients with Diffuse Large B-Cell Lymphoma Using Dexrazoxane and a Drug Combination

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany The Netherlands Spain

  • Study on Acalabrutinib with Rituximab and Drug Combination for Older Adults with Untreated Diffuse Large B-Cell Lymphoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Greece

  • Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Norway Sweden

  • Study on Immune Markers for Checkpoint Inhibitor Toxicity in Cancer Patients Using Atezolizumab, Dexamethasone Sodium Phosphate, and Alizapride

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium

  • Study of Izalontamab Brengitecan versus Platinum-based Chemotherapy for Patients with EGFR-mutated Non-small Cell Lung Cancer after EGFR Inhibitor Treatment

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +4

Glossary

  • Neutropenia: A condition characterized by an abnormally low count of neutrophils, a type of white blood cell important for fighting infections.
  • Febrile Neutropenia: A condition where a patient has both a fever (usually defined as a temperature of 38.3°C or higher) and a low neutrophil count, indicating an increased risk of serious infection.
  • Absolute Neutrophil Count (ANC): A measure of the number of neutrophils in the blood, used to assess the severity of neutropenia and monitor recovery.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • Biosimilar: A biological product that is highly similar to an already approved biological drug, with no clinically meaningful differences in terms of safety, purity, and potency.
  • Myelosuppressive Chemotherapy: Chemotherapy that suppresses the production of blood cells in the bone marrow, often leading to neutropenia and increased infection risk.
  • Subcutaneous (SC) Injection: An injection given into the fatty tissue just beneath the skin.
  • Granulocyte Colony-Stimulating Factor (G-CSF): A protein that stimulates the bone marrow to produce granulocytes (including neutrophils) and stem cells and release them into the bloodstream.
  • Duration of Severe Neutropenia (DSN): The number of consecutive days a patient experiences severe neutropenia, often defined as an ANC below 0.5 × 10^9/L.

References

  1. https://clinicaltrials.gov/study/NCT01516736
  2. https://clinicaltrials.gov/study/NCT01735175
  3. https://clinicaltrials.gov/study/NCT03202927
  4. https://clinicaltrials.gov/study/NCT03102606
  5. https://clinicaltrials.gov/study/NCT02044276
  6. https://clinicaltrials.gov/study/NCT03206229
  7. https://clinicaltrials.gov/study/NCT04345900
  8. https://clinicaltrials.gov/study/NCT01585649